Iron content of the brain is the main outcome in both the open...

Iron content of the brain is the main outcome in both the open and the placebo-controlled studies. Only after that comes alpha-synuclein, neurofilament light, and the subjective scores of the patient. So, despite these studies being MSA studies, the focus is the ability of ATH434 to reduce iron content in the brain.

If ATH434 can reduce iron from the brain, there will be many, in fact very many potential additional indications. Friedrich ataxia and this hypothalamus are included in my list just this month but brain injury, vascular stroke, subarachnoidal bleeding, Alzheimer's, different other dementias, and macula degeneration have been on my list much longer. According to several annular reports, most of these are also on ATH's list. Atherosclerosis is also a possibility, perhaps.

There are also non-brain-related diseases that could benefit from iron chelation. But first things first and now we need info about the MSA and soon about PD brains.